

Rameda Initiates First Acquisition of 2025 : Enhancing Chronic Portfolio with Key Acquisitions with Exposure to a 1.3 Billion EGP Market

7 July 2025 | Cairo, Egypt

Continuing its strategic expansion in the chronic care market, Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. (RMDA.CA on the EGX), a leading Egyptian pharmaceutical company, today **announced strategic acquisitions that further strengthen its position in key therapeutic areas**. This aligns with **Rameda's commitment to expanding its portfolio of recurring-revenue products in chronic therapeutic areas with accretive margins**.

This acquisition encompasses a portfolio of two products focused on addressing conditions within the Central Nervous System (CNS) and pain management, aligning with Rameda's commitment to expanding its presence in high-growth, specialized segments. Targeting major depressive disorders and anxiety with the first product, and addressing neuropathic pain, and generalized anxiety disorder with the second product.

These areas represent significant market opportunities, with the combined markets, where the acquired product lines are leading products, valued at over EGP 1.3 billion and demonstrating a 3-Year CAGR above 25%. The acquisition is projected to deliver immediate profitability, contributing positively to Rameda's financial performance starting in the second half of 2025.

The acquired portfolio boasts an accretive profitability profile compared to Rameda's existing portfolio, promising to enhance overall margins and drive sustainable growth. With this strategic move, Rameda continues to execute on its inorganic molecule acquisition strategy, acquiring products that generate tangible value and recurring revenue streams, and increasing its shift towards the chronic medication segment.

"We are excited to add this leading portfolio of differentiated products focused on the high-growth CNS and pain management areas," **said Dr. Amr Morsy, CEO of Rameda**. "These therapeutic areas align perfectly with our strategic focus on expanding our chronic care offerings and will further enhance our ability to provide patients with innovative and effective treatment options."

"This transaction represents a first step in our acquisition strategy for 2025," **said Mahmoud Fayek, COO and CFO of Rameda**. "Similar to our successful acquisition of the leading Anti-diabetic brand last year, we aim to secure acquisitions that generate significant value and enhance our portfolio. Depending on the opportunities available, this may involve acquiring a single, impactful product or a collection of strategic products, as we have done today. **We remain actively engaged in pursuing additional acquisitions to meet this target and further build on our commitment to delivering sustainable growth and enhancing shareholder value. We are confident that these products will contribute significantly to our revenue and profitability growth, solidifying our position as a leading player in the Egyptian pharmaceutical market.**"

-Ends-

Investor Relations Contact:

Khaled Daader
Head of Mergers and Acquisitions and Investor Relations
Email : khaled.daader@rameda.com

About Rameda

Established in 1986, Rameda (RMDA.CA on EGX) is a leading Egyptian pharmaceutical company led by a team of professionals with extensive multinational experience. The company develops and produces a wide range of branded generic pharmaceuticals, nutraceuticals, food supplements and veterinary products. Rameda combines global standards with local insights and a customer-centric approach. It has developed a broad portfolio of products across multiple therapeutic areas by successfully leveraging its strong product portfolio with its accretive product acquisitions to become one of the fastest-growing pharmaceutical players in Egypt. The company produces its wide range of dosage forms at its three manufacturing facilities located at its industrial complex in Cairo's Sixth of October Industrial Zone.

Forward-Looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "anticipates", "assumes", "believes", "could", "estimates", "expects", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would", or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding our business and management, our future growth or profitability and general economic and regulatory conditions and other matters affecting us.

Forward-looking statements reflect our management's ("Management") current views of future events, are based on Management's assumptions, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause our actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements. Our business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate, or prediction to become inaccurate. These risks include fluctuations in the prices of raw materials or employee costs required by our operations, its ability to retain the services of certain key employees, its ability to compete successfully, changes in political, social, legal, or economic conditions in Egypt, worldwide economic trends, the impact of war and terrorist activity, inflation, interest rate and exchange rate fluctuations, and Management's ability to timely and accurately identify future risks to our business and manage the risks mentioned above. Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly to the total figure given.